Success takes the right partner and strong systems.
ATN's Franchise Lens shares the keys to preparing for franchise success.
New research shows GLP-1 users are shelling out roughly $449 a month on fitness amid broader lifestyle shifts, although the general consensus is conflicted on whether weight-loss drugs are a net benefit for the fitness and wellness industry
In a new study, waist circumference proved a better predictor of mortality than BMI among older adults, supporting a broader shift in fitness from tracking scale weight to measuring fat, muscle and metabolic health
The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based medicines
Nestle believes the drugs are also creating a new market for products designed to address the side effects of rapid weight loss
Gyms are evolving to keep up with climbing GLP-1 adoption, offering muscle-preservation workouts, telehealth partnerships and integrated wellness services
More than 25% of GLP-1 users in the U.K. reported increasing fitness spending after starting treatment. Those results are promising, but other data shows it's far from a given that weight-loss drugs will prove to be a net benefit for the industry
Fitbit data from 750 adults found that daily movement and exercise levels declined after people started taking GLP-1 weight-loss drugs.
Early clinical trial results show that apitegromab dramatically reduced lean mass loss in people taking tirzepatide, the main ingredient in Mounjaro.
While improved health awareness and aging populations have also boosted whey prices, the GLP-1 trend is the key factor behind demand.
Despite the ubiquity of GLP-1s, only a small percentage of people are currently using them, according to a new report from Reach3 Insights.
Sign Up to Our Newsletter
